Since March 2018, P.A.I.N. (Prescription Addiction Intervention Now), an organization founded in 2017 by photographer Nan Goldin, has held demonstrations at art museums in New York, Washington, DC, Boston, London and Paris to protest their acceptance of money from the Sackler family, owners of Purdue Pharma, a company that been accused of fomenting the prescription opioid addiction crisis.
E-cigarette smoke, like tobacco smoke, may, in fact, cause cancer, new studies suggest.
Global health organizations, federal health agencies, and cancer epidemiology experts say they aren't swayed by just-published recommendations on consumption of red and processed meat.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
The National Medical Products Administration in China approved Merck's Keytruda as monotherapy for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1, with no EGFR or ALK genomic tumor aberrations.
Adding Kisqali (ribociclib) to standard hormone therapy significantly extended overall survival for postmenopausal patients with HR+/HER- advanced breast cancer in the phase III MONALEESA-3 trial.
The phase III CheckMate -067 trial continued to demonstrate improved overall survival with the first-line combination of Opdivo (nivolumab) plus Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced metastatic melanoma.
Jevtana (cabazitaxel) demonstrated improved survival over second androgen receptor-targeted agent in patients with metastatic castration-resistant prostate cancer. The data were published Sept. 30 in The New England Journal of Medicine.
Estimated rate of freedom from recurrence of breast cancer at a distant site was 93% at five years, an outcome much better than expected with endocrine therapy alone, data from the TAILORx trial show.
Verzenio (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer previously treated with endocrine therapy.
